Strand Therapeutics Sales Surge
Trigger: $153M Series B at Strand Therapeutics. Target CEO Jacob Becraft. Pitch: GMP-ready mRNA scale-up & AI-driven R&D tools. Fuel your pipeline now.
Published on
Do not index
Do not index
🚀 Battle Card: Strand Therapeutics
Quick trigger:
👤 Decision Maker in the News
- Jacob Becraft, Ph.D., CEO & Co-Founder 📧 jacob.becraft@strandtx.com
💡 Why It Matters
- Programmable mRNA that "thinks" enables real-time disease-responsive treatments with precision. → Source
🎯 Core Pain Point
- Complex scale-up of self-amplifying/circular RNA manufacturing
- Need seamless integration of computational design tools to accelerate R&D
💰 What to Pitch
- Primary: Scalable mRNA production platform → Robust, GMP-ready manufacturing at scale
- Expansion: AI-driven design and analytics tools → Faster candidate screening and optimization
Align pitch with the Strand Therapeutics sales trigger for best timing.
🗺️ Quick Context
- HQ: Cambridge, MA
- Employees: ≈ 50
- Rev: ≈ $0.5M
- Website: strandtx.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Strand Therapeutics’ business.*
- Catalent Biologics — mRNA manufacturing services
- Unique edge: Global CDMO with mRNA GMP capabilities
- Evaluated by COO & VP Ops for scale readiness
- Thermo Fisher Scientific — Reagent and platform solutions
- Unique edge: End-to-end reagent supply chain
- Evaluated by Dir. Finance for cost predictability
- Benchling — R&D software platform
- Unique edge: Integrated molecule-to-manufacturing informatics
- Evaluated by Head of R&D for collaboration efficiency
- Dotmatics — Scientific data management
- Unique edge: Customizable informatics workflows
- Evaluated by IT & Lab Ops for integration flexibility
✅ Do-Now Checklist
Connect with all decision makers on LinkedIn (links above)
Generate email + DM with the Copy-My-Prompt block (Step 7) referencing the Strand Therapeutics sales trigger and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Never miss a Strand Therapeutics sales trigger—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑Scalable mRNA production platform – Robust, GMP-ready manufacturing at scale❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Jacob
COMPANY = Strand Therapeutics
DEPT = Manufacturing
SIZE = ≈50
BOTTLENECK = Complex scale-up of self-amplifying/circular RNA manufacturing
EVENT = Scoops Up $153M Series B
DETAIL = Series B funding
PAIN = Need seamless integration of computational design tools to accelerate R&D
SRC = https://vcnewsdaily.com/strand-therapeutics/venture-capital-funding/zlmqzvqzcp
SIM_CO = Moderna
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈200
EMP_EST = ≈50
REV_EST = ≈$0.5M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈50-person Manufacturing
Jacob—noticed your Manufacturing team is ≈50.
That’s when Complex scale-up of self-amplifying/circular RNA manufacturing slows growth.
We helped Moderna fix this with Scalable mRNA production platform – Robust, GMP-ready manufacturing at scale.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈200.
DM ≤45 words, TONE:
Saw your post about Series B funding — Need seamless integration of computational design tools to accelerate R&D.
Scalable mRNA production platform – Robust, GMP-ready manufacturing at scale. ≈ TBD.
Quick chat?